“…In HCC, treatment with LDN-212854 repressed ID1 and EpCAM expression in cancer cells in vivo , suggesting that the repression of the BMP-9-induced CSC phenotype was attenuated by the inhibitor ( Chen et al, 2021 ). In brain tumors, ovarian cancer, lung cancer, oral squamous cell carcinoma, endometrial cancer, and melanoma, the therapeutic benefits of ALK2 inhibitors are suggested ( Langenfeld et al, 2013 ; Hao et al, 2014 ; Hover et al, 2015 ; Peng et al, 2016 ; Newman et al, 2018 ; Yin et al, 2018 ; Mihajlović et al, 2019 ; Zhou et al, 2020 ; Fukuda et al, 2021 ; Kalal et al, 2021 ). Our research group recently reported that a BMP type I receptor inhibitor, RK-783, inhibited the growth of ovarian cancer cells in vivo ( Fukuda et al, 2020 ).…”